Kizilkilic Esra Kochan, Unkun Rumeysa, Uygunoglu Ugur, Delil Sakir, Ozkara Cigdem
Department of Neurology, Cemil Taşcıoğlu City Hospital, Istanbul, Turkey.
Department of Neurology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey.
Eur J Neurol. 2022 Sep;29(9):2861-2863. doi: 10.1111/ene.15440. Epub 2022 Jun 22.
COVID-19 is a novel infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in which neurological complications have been increasingly recognized. Acute symptomatic epileptic seizures and status epilepticus are frequently reported neurological complications associated with this infection. The nervous system damage caused by SARS-CoV-2 may be mediated by the immune system. Interleukin 6 (IL-6), an important component of the cytokine storm, is directly correlated with the severity of symptoms. Tocilizumab is an inhibitor of IL-6 receptors, which blocks IL-6-mediated signal transduction and is used in the treatment of COVID-19 and status epilepticus.
A patient with the Unverricht-Lundborg disease is presented who had developed refractory recurrent status epilepticus during COVID-19 infection, which was finally controlled by treatment with tocilizumab.
Tocilizumab, an IL-6 inhibitor, may be considered as a treatment option in patients with status epilepticus and refractory seizures.
新型冠状病毒肺炎（COVID-19）是由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的一种新型传染病，其神经系统并发症已日益受到关注。急性症状性癫痫发作和癫痫持续状态是该感染常见的神经系统并发症。SARS-CoV-2造成的神经系统损害可能由免疫系统介导。白细胞介素6（IL-6）作为细胞因子风暴的重要组成部分，与症状严重程度直接相关。托珠单抗是一种IL-6受体抑制剂，可阻断IL-6介导的信号转导，用于治疗COVID-19和癫痫持续状态。
本文介绍了一名患有翁韦里希特-伦德伯格病的患者，该患者在COVID-19感染期间出现难治性复发性癫痫持续状态，最终通过托珠单抗治疗得到控制。
托珠单抗作为一种IL-6抑制剂，可被视为癫痫持续状态和难治性癫痫患者的一种治疗选择。
